

1/48

FIG. 1A – (SEQ ID NO: 1)

MLRLLLALNLFPSIQVTGNKILVKQSPMLVAYDNAVNLSCKYSYNLFSREFRSLH
KGLDSAVEVCVVYGNYSQQLOVYSKTGFNCDGKLGNESVTFYLQNLVYNQTDIYFC
KIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPFPGPSKPFWVLVVVGVLACYSL
Hinge Domain Transmembrane
LVTVAFIIFWVRSKRSRLHSDYMNMTPRRPGPTRKHYOPYAPPRDFAAYRS
Domain Signaling Domain

FIG. 1B**FIG. 1C**

FIG. 2A – Anti-CLL-1 Binding Molecules

	FR1	CDR1	FR2	CDR2
24C1_VH	QVQLQESGPGLVKPSSETLSLTCTVSGGSISS--YYWSWIRQPPGKGLEWIGYTIYSGS-T			
24C8_VH	QVQLQESGPGLVKPSQTLSTCTVSGGSISSGGFYWSWIRQHPGKGLEWIGYTIHHSQS-T			
20C5.1_VH	QVQLVQSGAEVKKPGASVKVSCKVSGYTLT--EISMHWVRQAPGKGLEWMGGEDPEDGET			
20C5.2_VH	QVQLVESGGGVVQPGRSLRLSCAASGFTFSS--YGMHWVRQAPGKGLEWVAVISYDGSDK			
	**** : ** : : . : : : * . * : : : * : * : * : * : * : * : * : * : * : *			
	FR3	CDR3	FR4	
24C1_VH	NYNPSLKSRVTISVDTSKNQFSLKLESSVIAADTAVYYCVSLVYCGGDCYSGFDYWGQGTL			
24C8_VH	HYNPSLKSRVTISIDTSKNLESLRLSSVIAADTAVYYCASLVYCGGDCYSGFDYWGQGTL			
20C5.1_VH	IYAQKFQGRVTITVEDTSTDTAYMELSSLRSEDTAVYYCATESRGIG--WEYFDYWGQGTL			
20C5.2_VH	YYVDSVKGRFTISRDN SKNRLYLQMNSLR AEDTAVYYCARERYSG-----RDYWGQGTL			
	* * . * : * . * : : . : . * : : * : * : * : * : * : * : * : *			
	FR4			
24C1_VH	VTVSS			
24C8_VH	VTVSS			
20C5.1_VH	VTVSS			
20C5.2_VH	VTVSS			

FIG. 2B	SEQ ID NO:			
	VH	CDR1	CDR2	CDR3
24C1 VH	125	93	97	101
24C8 VH	126	94	98	102
20C5.1 VH	127	95	99	103
20C5.2 VH	128	96	100	104

	FR1	CDR1	FR2	CDR2	FR3
24C1_VL	DIQLTQSPSSLSASVGDVRVSETCCQASQDINNFLNWKYQQKPGKAPKELTYDASNLETGVPS				
24C8_VL	DIQLTQSPSSLASAVGDRVSFETCCQASQDINNFLNWKYQQKPGKAPKLIIYDASNLETGVPS				
20C5.1_VL	DIQM T Q S P S S L S A S V G D R V T I T C F A S Q S I S S Y L N W K Y Q Q K P G K A P K L L I S G A S S L K S G V P S				
20C5.2_VL	EIVMTQSPTATLSVSPGERATLSCRASQSVSSLLTWYQCKPQCQAPRLIEFGASTRAITGIPA :* :*****:* * *:.*.:*:***:. . . * :*****:* :*****.**.* :*				
	FR3	CDR3	FR4		
24C1_VL	RESGSGSGTDFTFTISSLPEDIAITYYCQQYGNLPETFGGGTKEVEIKR				
24C8_VL	RESGSGSGTDFTFTISSLPEDIAITYYCQQYGNLPETFGGGTKEVEIKR				
20C5.1_VL	RFSGSGSGTDFTFTISSLPEDIFATYYCQQSYSTPIITFCQGTRLEIQR				
20C5.2_VL	RFSGSGSGTGFTTLTISSLOSEDFAVYYCQQYDTWPFTFCPGTKVDVKR *****:* * *****:**:* ***:*****:				

<u>FIG. 2D</u>	SEQ ID NO:			
	VL	CDR1	CDR2	CDR3
24C1 VL	125	93	97	101
24C8 VL	126	94	98	102
20C5.1 VL	127	95	99	103
20C5.2 VL	128	96	100	104

FIG. 2E – Anti-BCMA Binding Molecules


	FR1	CDR1	FR2	CDR2
FS-21495 VH	EVQLLES GGG LVQPGGSLRLSCAASG	--FTFSSYAMS WVRQAPGKGL	EWVS	AISSGGSGST
PC-21497 VH	QVQLVES GGG VQPGERSLRLSCAASG	--FTFSSYGMH WVRQAPGKGL	EWVAVI	SYDGSNK
AJ-21508 VH	QVQLVQSGAEVKKPGASVKVCKASG	--YTFTSYMH WVRQAPGQGL	EWMMGI	INPGGGST
NM-21517 VH	QLQLQES GPGLVKPS ETLQLTCTVSGG	SISSSYWG WIRQPPGKGL	EWIGSI	SYSG-ST
TS-21522 VH	EVQLVES GGG LVQPGGSLRLSCAASG	--FTFSSYSMN WVRQAPGKGL	EWVSTI	SSSSSTI
RY-21527 VH	QVQLVES GGG VQPGERSLRLSCAASG	--FTFSSYGMH WVRQAPGKGL	EWVAVI	SYDGSNK
PP-21528 VH	QVQLVQSGAEVKKPGSSVKVCKASG	--GTFSSYAI S WVRQAPGQGL	EWMMGI	PIPIFGTA
RD-21530 VH	QVQLVES GGG VQPGERSLRLSCAASG	--FTFSSYGMH WVRQAPGKGL	EWVAVI	SYDGSNK
	::** :*** : :*. :: : :* .*	***	***,***:****, *	.
	CDR2	FR3	CDR3	
FS-21495 VH	YYADSVKGRFTISRDN SKNTLYLQMNS	LRAEDTAVYYC	AR-AEM-----	GAVFDI WGQ
PC-21497 VH	YYADSVKGRFTISRDN SKNTLYLQMNS	LRAEDTAVYYC	ARDGTYLGGL---	WY-FDIWGR
AJ-21508 VH	SYAQKFGGRVTIMTRDTSTVYME	LSLRSED TAVYYC	AR-----	ESWPM DVWGQ
NM-21517 VH	YYNPSLKSRVTISVDTSKNQESLKL	SSVTAAD TAVYYC	ARGRGYATS-----	LAFDI WGQ
TS-21522 VH	YYADSVKGRFTISRDN AKNSLYLQMNS	LRAEDTAVYYC	ARCSQE-----	HLIEDY WGQ
RY-21527 VH	YYADSVKGRFTISRDN SKNTLYLQMNS	LRAEDTAVYYC	ARTDEWSGSP---	PG-LDYWGQ
PP-21528 VH	NYAQKEGGRVTITADESTSTAYME	LSLRSED TAVYYC	ARTPEYSSSIWHY	YYYGMDV WGQ
RD-21530 VH	YYADSVKGRFTISRDN SKNTLYLQMNS	LRAEDTAVYYC	VKGPLQEPFY---	DYGM DVWGQ
	* ..*.*.*: * .. : : :* : : *****	..	:* **:	
	FR4			
FS-21495 VH	GTMVTVSS			
PC-21497 VH	GTLVTVSS			
AJ-21508 VH	GTTVTVSS			
NM-21517 VH	GTMVTVSS			
TS-21522 VH	GTLVTVSS			
RY-21527 VH	GTLVTVSS			
PP-21528 VH	GTTVTVSS			
RD-21530 VH	GTTVTVSS			
	** *****			

FIG. 2F	SEQ ID NO:			
	VH	CDR1	CDR2	CDR3
FS-21495 VH	77	13	21	29
PC-21497 VH	78	14	22	30
AJ-21508 VH	79	15	23	31
NM-21517 VH	80	16	24	32
TS-21522 VH	81	17	25	33
RY-21527 VH	82	18	26	34
PP-21528 VH	83	19	27	35
RD-21530 VH	84	20	28	36

FIG. 2G – Anti-BCMA Binding Molecules

	FR1	CDR1	FR2	CDR2
FS-21495_VL	EIVLTQSPATLSLSPGERATLSCRASQSVSR-----YLA	NYQOKPGQAPRLLIYDASNR		
PC-21497_VL	DIVMTQSPFLSLPVTFGEPAISCRSSQSLHNSG-YNYLE	WYLQKPGQSPQLLIYLGSNR		
AJ-21508_VL	EIVMTQSPATLSVSPGERATLSCRASQSVSS-----NL	ANYQOKPGQAPRLLIYGASTR		
NM-21517_VL	EIVLTQSPATLSLSPGERATLSCRASQSVSS-----YLA	NYQOKPGQAPRLLIYDASNR		
TS-21522_VL	EIVLTQSPATLSLSPGERATLSCRASQSVSR-----YLA	NYQOKPGQAPRLLIYDASNR		
RY-21527_VL	DIQLTQSPSSVSASVGDRTITCRASQGISS-----WL	ANYQOKPGKAPKLLIYGASSL		
PP-21528_VL	DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLA	NYQOKPGQFPKLLIYWASTR		
RD-21530_VL	EIVMTQSPATLSVSPGERATLSCRASQSVSS-----NL	ANYQOKPGQAPRLLIYSASTR		
	:* :**** :. : * : :. :* :**** : *	*** :* :**** :*		
	CDR2	FR3	CDR3	FR4
FS-21495_VL	ATGIPARFSGSGSGTDFTLTISSLPEDEFAVYYCQQRISWPF	TEGGGTKVEIK		
PC-21497_VL	ASSVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGLGLPL	TEGGGTKVEIK		
AJ-21508_VL	ATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQYAAYP-	TEGGGTKVEIK		
NM-21517_VL	ATGIPARFSGSGSGTDFTLTISSLPEDEFAVYYCQQRHVWPP	TEGGGTKVEIK		
TS-21522_VL	ATGIPARFSGSGSGTDFTLTISSLPEDEFAVYYCQRFYYPWF	TEGGGTKVEIK		
RY-21527_VL	QSSVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQIYTFPF	TEGGGTKVEIK		
PP-21528_VL	ESSVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQFAHTPF	TEGGGTKVEIK		
RD-21530_VL	ATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQHHVWPL	TEGGGTKVEIK		
	:* * ***** :**** * : : * :. : * * *			

FIG. 2H	SEQ ID NO:			
	VL	CDR1	CDR2	CDR3
FS-21495_VL	85	37	45	53
PC-21497_VL	86	38	46	54
AJ-21508_VL	87	39	47	55
NM-21517_VL	88	40	48	56
TS-21522_VL	89	41	49	57
RY-21527_VL	90	42	50	58
PP-21528_VL	91	43	51	59
RD-21530_VL	92	44	52	60



7/48

FIG. 4A

Namalwa IFN γ




FIG. 4B

Namalwa IFN γ




FIG. 4C

Namalwa IL-2




FIG. 4D

Namalwa IL-2




FIG. 4E

Namalwa TNF α




FIG. 4F

Namalwa TNF α




FIG. 4G




FIG. 4H




FIG. 4I




FIG. 4J




FIG. 4K





FIG. 4L



9/48

FIG. 4M




FIG. 4N




FIG. 4O




FIG. 4P




FIG. 4Q





FIG. 4R



10/48

FIG. 4S




FIG. 4T




FIG. 4U




FIG. 4V




FIG. 4W











FIG. 4X













FIG. 6A









FIG. 6B











FIG. 8A




FIG. 8B




FIG. 8C




FIG. 8D





FIG. 9A **Donor 1**



■ Unstimulated T cells ■ T cells + indicated stimulus





FIG. 10A

Mock



Protein L

FIG. 10B

10E3-CHD




FIG. 10C

10E3-THD




FIG. 10D

8B5-THD




FIG. 10E

Mean (+/- Standard Deviation)





FIG. 10F

Median (+/- Interquartile Range)



25/48

FIG. 10G

Day	Mock vs 10E3-CHD	Mock vs 10E3-THD	Mock vs 8B5-THD	10E3-THD vs 8B5-THD
6	0.756	0.657	0.690	0.959
13	0.067	0.0004	0.0002	0.028
20	0.777	0.0022	0.0020	0.639
27	0.158	<0.0001	<0.0001	0.042
34	0.200	0.0004	0.0001	0.142
41	0.376	0.0072	0.0009	0.054

26/48

FIG. 10H





FIG. 10I



27/48



FIG. 10J**FIG. 10K**

FIG. 11B






FIG. 11A




Protein L


29/48



FIG. 12A

30/48

FIG. 12B

31/48

FIG. 12C










FIG. 13E




35/48

FIG. 14A


36/48

FIG. 14B


37/48

FIG. 14C

38/48

FIG. 15A

39/48

FIG. 15B

40/48


FIG. 15C

FIG. 16A




FIG. 16B




FIG. 16C





FIG. 16D



43/48

FIG. 16E





FIG. 16F



44/48

FIG. 17A




FIG. 17B




FIG. 17C

NCI-H929





FIG. 17D

NCI-H929



46/48

FIG. 17E




FIG. 17F




FIG. 19A




FIG. 19B

